Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 3.5% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shot up 3.5% during mid-day trading on Friday . The stock traded as high as $0.28 and last traded at $0.26. 29,962,066 shares were traded during mid-day trading, a decline of 57% from the average session volume of 68,989,281 shares. The stock had previously closed at $0.26.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research report on Thursday. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Up 8.9 %

The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The firm has a 50 day moving average price of $0.25 and a two-hundred day moving average price of $0.32. The company has a market capitalization of $52.09 million, a price-to-earnings ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.